We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
India’s drug pricing authority is proposing a requirement to display special markings and ceiling prices on labels for life-saving and essential drugs, an idea that one observer says should have included input from the country’s drug regulator. Read More
Global sales of pharmaceuticals are expected to surge 30 percent to $1.3 trillion by 2018, as more high-priced therapies enter the market and fewer drugs face generic competition, a new study finds. Read More
The FDA wants to refine the methods it uses to assess patient perception of risk and benefit information in direct-to-consumer advertising, aiming to design more accurate DTC ad studies that don’t overtax the subjects. Read More
Mylan said earlier this month that it has launched a generic version of Warner Chilcott’s oral contraceptive Loestrin 24 Fe in the U.S., following final FDA approval. Read More
Biosimilars are expected to account for roughly 4 percent of all biologics sales over the next 10 years, saving the U.S. healthcare system an estimated $44.2 billion, according to new research that forecasts significantly lower savings from the products than another widely cited study. Read More
The number of patent lawsuits filed over generic drug challenges has spiked this year, a development that coincides with the widely anticipated “patent cliff” of many brand drugs losing protection. Read More
AstraZeneca has filed a patent infringement lawsuit against Actavis subsidiary Watson over a proposed generic version of AZ’s diabetes drug Kombiglyze XR. Read More
A federal judge has dismissed claims brought by a group of pharmacies that Pfizer and Ranbaxy forged an illegal deal to delay generic competition to Pfizer’s cholesterol drug Lipitor, marking another victory for the manufacturers in the class action filing. Read More
HHS decided not to issue an all-encompassing regulation on the 340B drug pricing program as intended, but will keep in place its earlier interpretive rule that requires manufacturers to provide certain orphan drugs at discounts of up to 50 percent. Read More
Pharmaceutical companies today spend an average of $2.6 billion to get their products to market, according to a new report that finds R&D costs have increased 145 percent over the past decade. Read More